277 related articles for article (PubMed ID: 30726732)
61. Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.
Murphy PM; Heusinkveld L
Cytokine; 2018 Sep; 109():2-10. PubMed ID: 29398278
[TBL] [Abstract][Full Text] [Related]
62. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
63. Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function.
Cheng YH; Eby JM; LaPorte HM; Volkman BF; Majetschak M
PLoS One; 2017; 12(11):e0187949. PubMed ID: 29125867
[TBL] [Abstract][Full Text] [Related]
64. Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation
Janssens R; Boff D; Ruytinx P; Mortier A; Vanheule V; Larsen O; Daugvilaite V; Rosenkilde MM; Noppen S; Liekens S; Schols D; De Meester I; Opdenakker G; Struyf S; Teixeira MM; Amaral FA; Proost P
Front Immunol; 2018; 9():1933. PubMed ID: 30233568
[TBL] [Abstract][Full Text] [Related]
65. CXCR4/ACKR3 Phosphorylation and Recruitment of Interacting Proteins: Key Mechanisms Regulating Their Functional Status.
Fumagalli A; Zarca A; Neves M; Caspar B; Hill SJ; Mayor F; Smit MJ; Marin P
Mol Pharmacol; 2019 Dec; 96(6):794-808. PubMed ID: 30837297
[TBL] [Abstract][Full Text] [Related]
66. Crosstalk between CXCR4/ACKR3 and EGFR Signaling in Breast Cancer Cells.
Neves M; Marolda V; Mayor F; Penela P
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233192
[TBL] [Abstract][Full Text] [Related]
67. Expression and function of CXCR7 in the mouse forebrain.
Tiveron MC; Boutin C; Daou P; Moepps B; Cremer H
J Neuroimmunol; 2010 Jul; 224(1-2):72-9. PubMed ID: 20681075
[TBL] [Abstract][Full Text] [Related]
68. From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function.
Smit MJ; van Muijlwijk-Koezen JE
Mol Pharmacol; 2019 Dec; 96(6):735-736. PubMed ID: 31624136
[TBL] [Abstract][Full Text] [Related]
69. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
70. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
71. Distinct Activation Mechanisms of CXCR4 and ACKR3 Revealed by Single-Molecule Analysis of their Conformational Landscapes.
Schafer CT; Pauszek RF; Gustavsson M; Handel TM; Millar DP
bioRxiv; 2024 Jun; ():. PubMed ID: 37961571
[TBL] [Abstract][Full Text] [Related]
72. AMD3100 is a CXCR7 ligand with allosteric agonist properties.
Kalatskaya I; Berchiche YA; Gravel S; Limberg BJ; Rosenbaum JS; Heveker N
Mol Pharmacol; 2009 May; 75(5):1240-7. PubMed ID: 19255243
[TBL] [Abstract][Full Text] [Related]
73. Biased antagonism of CXCR4 avoids antagonist tolerance.
Hitchinson B; Eby JM; Gao X; Guite-Vinet F; Ziarek JJ; Abdelkarim H; Lee Y; Okamoto Y; Shikano S; Majetschak M; Heveker N; Volkman BF; Tarasova NI; Gaponenko V
Sci Signal; 2018 Oct; 11(552):. PubMed ID: 30327409
[TBL] [Abstract][Full Text] [Related]
74. CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma.
Rusetska N; Kowalski K; Zalewski K; Zięba S; Bidziński M; Goryca K; Kotowicz B; Fuksiewicz M; Kopczynski J; Bakuła-Zalewska E; Kowalik A; Kowalewska M
J Clin Pathol; 2022 May; 75(5):324-332. PubMed ID: 33692092
[TBL] [Abstract][Full Text] [Related]
75. Pharmacological Characterization and Radiolabeling of VUF15485, a High-Affinity Small-Molecule Agonist for the Atypical Chemokine Receptor ACKR3.
Zarca AM; Adlere I; Viciano CP; Arimont-Segura M; Meyrath M; Simon IA; Bebelman JP; Laan D; Custers HGJ; Janssen E; Versteegh KL; Buzink MCML; Nesheva DN; Bosma R; de Esch IJP; Vischer HF; Wijtmans M; Szpakowska M; Chevigné A; Hoffmann C; de Graaf C; Zarzycka BA; Windhorst AD; Smit MJ; Leurs R
Mol Pharmacol; 2024 Mar; 105(4):301-312. PubMed ID: 38346795
[TBL] [Abstract][Full Text] [Related]
76. CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands.
Castaldo C; Benicchi T; Otrocka M; Mori E; Pilli E; Ferruzzi P; Valensin S; Diamanti D; Fecke W; Varrone M; Porcari V
J Biomol Screen; 2014 Jul; 19(6):859-69. PubMed ID: 24632660
[TBL] [Abstract][Full Text] [Related]
77. ACKR3-arrestin2/3 complexes reveal molecular consequences of GRK-dependent barcoding.
Chen Q; Schafer CT; Mukherjee S; Gustavsson M; Agrawal P; Yao XQ; Kossiakoff AA; Handel TM; Tesmer JJG
bioRxiv; 2023 Jul; ():. PubMed ID: 37502840
[TBL] [Abstract][Full Text] [Related]
78. CXC chemokine receptor 7 (CXCR7) affects the migration of GnRH neurons by regulating CXCL12 availability.
Memi F; Abe P; Cariboni A; MacKay F; Parnavelas JG; Stumm R
J Neurosci; 2013 Oct; 33(44):17527-37. PubMed ID: 24174685
[TBL] [Abstract][Full Text] [Related]
79. Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate.
Murad HAS; Rafeeq MM; Alqurashi TMA
Ann Med; 2021 Dec; 53(1):1598-1612. PubMed ID: 34494495
[TBL] [Abstract][Full Text] [Related]
80. Functional consequences of chemically-induced β-arrestin binding to chemokine receptors CXCR4 and CCR5 in the absence of ligand stimulation.
Liebick M; Henze S; Vogt V; Oppermann M
Cell Signal; 2017 Oct; 38():201-211. PubMed ID: 28733085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
